Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.40 |
| ▸ | HTR2C | P28335 | 14/20 | 0.40 |
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415814 | 1.00 | HTR2A (0.40) | HTR2AHTR2CDRD2HTR1ADRD4 | |
| SCHEMBL5407433 | 1.00 | HTR2A (0.40) | HTR2AHTR2CDRD2HTR1ADRD4 | |
| SCHEMBL5413940 | 0.96 | HTR2A (0.41) | HTR2AHTR2CDRD2HTR1ADRD4 | |
| SCHEMBL5420075 | 0.96 | HTR2A (0.41) | HTR2AHTR2CDRD2HTR1ADRD4 | |
| SCHEMBL5417815 | 0.96 | HTR2A (0.41) | HTR2AHTR2CDRD2HTR1ADRD4 | |
| SCHEMBL5421768 | 0.96 | HTR2A (0.38) | HTR2AHTR2CDRD2HTR1ADRD4 | |
| SCHEMBL5421771 | 0.96 | HTR2A (0.38) | HTR2AHTR2CDRD2HTR1ADRD4 | |
| SCHEMBL6812114 | 0.93 | HTR2A (0.39) | HTR2AHTR2CDRD2CCR3USP2 | |
| SCHEMBL5410734 | 0.93 | HTR2A (0.39) | HTR2AHTR2CDRD2CCR3USP2 | |
| SCHEMBL5410739 | 0.93 | HTR2A (0.39) | HTR2AHTR2CDRD2CCR3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | HTR2A 30/4885HTR2C 2/4885DRD2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.